We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen and Allergan claim their biosimilar candidate is clinically equivalent to Roche’s blockbuster Avastin in adult patients with advanced non-small cell lung cancer. Read More
California biopharmaceutical company Gilead is reporting the first single table regimen combining two drugs proved effective in treating all six genotypes of hepatitis C in four clinical trials. Read More
Boehringer Ingelheim and the BioMed X Innovation Center are using crowdsourcing to assemble a research team to identify new approaches to treat chronic obstructive pulmonary disease. Read More
Pfizer’s oral Xeljanz sent more patients suffering from moderate to severe ulcerative colitis into remission, meeting primary endpoints in two Phase 3 clinical trials, the company reported Monday. Read More
The FDA has awarded research grants totaling more than $19 million to boost the development of products to treat 17 different rare diseases, many of which have little or no available treatment options. Read More